Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.36 |
| ▸ | SMO | Q99835 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.36 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7182411 | 0.94 | KMT2A (0.40) | KMT2AMEN1GAAMAPTRAB9A | |
| SCHEMBL7188746 | 0.90 | MEN1 (0.39) | KMT2AMEN1GAAMAPTRAB9A | |
| SCHEMBL7174811 | 0.90 | TYK2 (0.44) | KMT2AGAAMAPTPTK2BTYK2 | |
| SCHEMBL15158 | 0.89 | LMNA (0.40) | KMT2AMEN1MAPTRAB9AALDH1A1 | |
| SCHEMBL7184527 | 0.89 | MEN1 (0.38) | KMT2AMEN1MAPTRAB9ATP53 | |
| SCHEMBL7182407 | 0.89 | CA12 (0.40) | KMT2AMEN1GAAMAPTRAB9A | |
| SCHEMBL7180487 | 0.88 | LMNA (0.37) | KMT2AMEN1MAPTRAB9AALDH1A1 | |
| SCHEMBL25250816 | 0.88 | LMNA (0.39) | KMT2AMEN1MAPTRAB9AALDH1A1 | |
| SCHEMBL30988127 | 0.88 | KMT2A (0.41) | KMT2AMEN1MAPTRAB9AALDH1A1 | |
| Lithium SCHEMBL30307090 | 0.88 | LMNA (0.39) | KMT2AMEN1MAPTRAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579663-B2 | Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-06-17 | — | — | US | disclosed |
| US-20020107413-A1 | Organometallic monoacylarylphosphines | WOLF JEAN-PIERRE (CH) | 2002-08-08 | — | — | US | disclosed |
| US-6399805-B2 | SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES | CIBA SPECIALTY CHEMICALS CORPORATION | 2002-06-04 | — | — | US | disclosed |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | CIBA SPECIALTY CHEMICALS CORP. | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107413-A1 | Organometallic monoacylarylphosphines | CBR1, NAF1, DHCR24 | KMT2A 1586/4885MEN1 2312/4885GAA 4753/4885 |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | NAF1, DHCR24, CBR1 | KMT2A 956/4885MEN1 2263/4885GAA 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.